Subcortical Surgery Group

Event

Immunotherapy and Newly Diagnosed GBM: Phase 1B Results and 2b Trial Overview

presented by Subcortical Surgery Group

49 others would like to attend.

Register Now

Notification icon Tuesday, May 4, 2021 6 PM - 7 PM America/New_York

Event info

Special Look at Phase 1b Imvax Study to Assess the Safety & Efficacy of IGV-001

  • Explore highest exposure cohort yielded significantly higher pro- inflammatory cytokine serum levels significant improvement
    in both PFS and OS over historical controls
  • Study methylated subgroup manifesting a 3-fold improvement in mPFS with mOS not yet reached
  • Deep dive with data lock, highest exposure cohort exhibiting significant improvement in both PFS and OS over
    historical controls

An Overview of Emerging Therapeutic Targets

  • Examine the current treatment options and emerging targeted therapies
  • If targeted therapies show limited efficacy as single agents, can the combination of several targeted therapies be of benefit
    to GBM patients?
  • Additional research is urgently required to identify therapeutic targets in GBM: How can the industry design novel therapeutic strategies for the treatment of GBM?
Faculty
  • David Andrews

    Research Presenter

49 others would like to attend.

Register Now


0 Comments
Login to view comments. Click here to Login